The movement of big pharma into biologics (biopharmaceuticals) understandably has a direct effect on the pharmaceutical landscape. Companies show a diminishing portfolio revenue from small molecule drugs, primarily because of patent expiration on blockbuster drugs (small molecules) and the reallocation of industry resources towards biologics.
Biologics represent one of the most promising frontiers in pharmacotherapy; USFDA approved more biologics in 2009, the figure includes 19 new molecular entities (NMEs) and six novel biologics. In 2008 FDA approved 21 NMEs and three novel biologics. A substantial improvement in biologics approvals in 2009. (fig.1, Nature Medicine, 139, 16, 2010). Moreover, it is expected to take over from small molecule field in the coming years (fig 2, Nature reviews / drug discovery). However, their cost can be substantial, reaching $200,000 or more annually for treatment (Cerezyme), and the large molecules drugs are administered via injection – a less popular option with patients.
Biologics are gradually going to replace the traditional approach to drug design. Students need to understand industries changing needs if they plan on carriers in this area.
No comments:
Post a Comment